iRhythm Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IRTC in the last 30 days.
See all $IRTC insider activity →iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.
Freedom Capital Markets kept a Buy rating and $190 price target on iRhythm Holdings, implying 74.2% upside from the Oct 5 close. The firm expects $1B+ revenue by 2027, 70%+ gross margin, and 15%+ EBITDA margin. The VitalConnect acquisition could add $65M in revenue within 12 months.
Wells Fargo lowered its price target on iRhythm Technologies (IRTC) to $150 from $168, citing updated models post-VitalPatch acquisition. IRTC trades at $109.09 with a $3.6B market cap. Analysts expect 62% upside. Q2 revenue was $224.2M, beating estimates. IRTC raised 2026 revenue guidance, targeting 15% adjusted EBITDA margin by 2027.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning IRTC (iRhythm Holdings, Inc.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 3 bearish.
Recent IRTC coverage spans financial news, mergers & acquisitions and earnings.
iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.
Freedom Capital Markets kept a Buy rating and $190 price target on iRhythm Holdings, implying 74.2% upside from the Oct 5 close. The firm expects $1B+ revenue by 2027, 70%+ gross margin, and 15%+ EBITDA margin. The VitalConnect acquisition could add $65M in revenue within 12 months.
Target cut suggests downside pressure as analysts reassess valuation post‑acquisition.
The deal adds wearable biosensor capabilities and broadens addressable market, likely supporting revenue growth and margin targets.
The breach likely creates negative sentiment and potential regulatory scrutiny.
AlphAI scores every news story that mentions IRTC with an AI model for sentiment and relevance, and aggregates insider trades from iRhythm Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.
3 min readFreedom Capital Markets kept a Buy rating and $190 price target on iRhythm Holdings, implying 74.2% upside from the Oct 5 close. The firm expects $1B+ revenue by 2027, 70%+ gross margin, and 15%+ EBITDA margin. The VitalConnect acquisition could add $65M in revenue within 12 months.
1 min readWells Fargo lowered its price target on iRhythm Technologies (IRTC) to $150 from $168, citing updated models post-VitalPatch acquisition. IRTC trades at $109.09 with a $3.6B market cap. Analysts expect 62% upside. Q2 revenue was $224.2M, beating estimates. IRTC raised 2026 revenue guidance, targeting 15% adjusted EBITDA margin by 2027.
2 min readiRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.
3 min readiRhythm Holdings (IRTC) reported that a June cyberattack accessed patient data, including names, contact info, and insurance numbers. The company is notifying affected individuals.
1 min readiRhythm Holdings (IRTC) reported data exfiltration in third-party apps from June 3-8, 2026, affecting patient and insurance data. The company began notifying impacted individuals and stated no material financial impact is expected. This follows a previous breach disclosure in June 2026.
1 min readiRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer
1 min readResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.
3 min readiRhythm Holdings (IRTC) acquired VitalConnect to expand its product portfolio, aiming for 30%-40% market share in the MCT sector. The deal leverages technology and a larger sales force for nationwide growth, with plans for EHR integration and multi-vitals capabilities, according to a Wells Fargo conference transcript.
1 min readiRhythm Holdings (IRTC) reported Q2 2026 revenues of $224.2M, up 20.1% YoY, and raised full-year guidance to $880-$890M. Gross margin expanded to 72.8%, and adjusted EBITDA grew over 1,000 bps YoY. However, risks include reimbursement uncertainties, execution challenges, and an unresolved FDA warning letter.
3 min read
